[Biostim in the treatment of recurrent respiratory diseases in children].
The authors treated with Biostim (Roussel Uclaf Co., France) 20 children aged 3 to 15 years with relapsing and chronic diseases of the respiratory system. A favourable clinical effect was observed in 45% and improvement in 40% of the patients. In the investigated immunological indicators the response to treatment Biostim was manifested in the antibody immunity by a reduction of IgE values (P < 0.01) and of IgM (P < 0.05). As to cellular immunity, there was a significant increase of the phagocytic activity (P < 0.05). The tolerance of the preparation was very good.
Kapellerová
A
A
II. detská klinika LF UK, Bratislava.
Sustrová
M
M
Cingelová
D
D
Kuková
Z
Z
Krovinová
A
A
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000293:Adolescent; D001426:Bacterial Proteins / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D006801:Humans; D012008:Recurrence; D012140:Respiratory Tract Diseases / Q000276:immunology / Q000628:therapy*
D000276:Adjuvants, Immunologic; D001426:Bacterial Proteins; C037567:glycoprotein, Klebsiella pneumoniae
Biostim v liecbe recidivujúcich respiracných chorôb u detí.